Zymogenetics.com isn't a thriving biotech startup—it's a digital ghost. The site redirects to Bristol Myers Squibb, yet the corporate parent lists it as a separate entity with 271 employees and $42M in revenue. This isn't a company; it's a corporate relic with zero organic web presence.

"This isn't a biopharma website—it's a digital tombstone for a failed acquisition strategy."

The tech stack tells the story of neglect: jQuery, Bootstrap, and Zendesk suggest a site frozen in 2015. No modern analytics, no conversion funnels, no content strategy. Yet the social profiles are all active under BMS, confirming the brand was fully cannibalized.

• Zero organic search presence despite biopharma's competitive content landscape
• Revenue exists but is invisible to digital channels—pure B2B government/contract work?
• Active social profiles point to BMS, not Zymogenetics—brand dissolution complete